Egnyte Creates Egnyte for Life Sciences Platform
Egnyte has announced Egnyte for Life Sciences, a purpose-built platform to serve those advancing the science of health. Egnyte’s solution aims to help biotech, medical device, and diagnostics companies accomplish three outcomes: meeting regulatory compliance standards, expedite data sharing and collaboration, and secure essential intellectual property.
The platform provides document management capabilities to facilitate intra- and inter-institutional collaboration while maintaining compliance with FDA 21 CFR Part 11 directives.
Egnyte is also announcing the formation of a Life Sciences Advisory Board to shape its offerings and go-to-market strategy in the industry.
Read the full release, here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
